Work

Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)

Year: 2006

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2006.24.18_suppl.lba3

Authors: R. J. Motzer, T. E. Hutson, P. Tomczak, M. D. Michaelson, R. M. Bukowski, O. Rixe, S. Oudard, S. T. Kim, C. M. Baum, R. A. Figlin

Institutions: Cleveland Clinic, Memorial Sloan Kettering Cancer Center, University of California, Los Angeles, Pfizer (United States), Massachusetts General Hospital, Hôpital Européen Georges-Pompidou, Pfizer (France), Pitié-Salpêtrière Hospital

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2950942979

Cites:

Cited by: 101

Related to: 10